Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
Healthcare
$9.12 +0.00%
+$0.00 today
- Market cap
- $605.45M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
52W Low $8.48High $24.25
Volume 0.84M
Average 0.54M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$155.60M
FY 2025 · Annual
Net Income
-$137.95M
FY 2025 · Annual
Income Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 31.31M | 30.62M | 63.62M | 125.1M |
| Selling, General & Admin | 6.34M | 9.27M | 18.77M | 30.51M |
| Operating Expenses | 37.66M | 39.89M | 82.39M | 155.6M |
| Depreciation & Amortization | 10K | 19K | 56K | 105K |
| EBITDA | (37.72M) | (51.96M) | (67.75M) | (137.63M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (37.66M) | (39.89M) | (82.39M) | (155.6M) |
| Operating Margin | — | — | — | — |
| Interest Income | 4K | 1.31M | 14.58M | 17.87M |
| Interest Expense | 112K | 0 | 0 | 0 |
| Other Income / Expenses | (188K) | (12.09M) | 14.58M | 17.87M |
| Income Before Tax | (37.84M) | (51.98M) | (67.81M) | (137.73M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1K | 5K | 187K | 217K |
| Net Income | (37.85M) | (51.99M) | (68M) | (137.95M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.73) | (1.00) | (1.25) | (2.52) |
| EPS (Diluted) | (0.73) | (1.00) | (1.25) | (2.52) |
| 51.76M | 51.76M | 54.42M | 54.68M | |
| 51.76M | 51.76M | 54.42M | 54.68M |
BCAX Earnings Waterfall · TTM
NASDAQ:BCAX · Revenue to Net Income
Key Ratios
EPS$-2.78
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-5.5
P/S Ratio0.0
Analysis
$0 of revenue converted into -$157.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.78, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-8 | S-8 filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 7, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 10, 2026 |
How much revenue does BCAX generate?
Bicara Therapeutics Inc. Common Stock (BCAX) reported $0.00 of revenue in fiscal 2025.
Is BCAX profitable?
Bicara Therapeutics Inc. Common Stock (BCAX) reported -$137.95M of net income.
Continue the stock analysis
Jump to another research area for this company.